Containing Emulsions, Dispersions, Or Solutions Patents (Class 424/455)
-
Patent number: 9000048Abstract: The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.Type: GrantFiled: November 28, 2007Date of Patent: April 7, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Sandro Mecozzi, Robert A. Pearce, Jonathan P. Fast
-
Publication number: 20150079164Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).Type: ApplicationFiled: March 15, 2013Publication date: March 19, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Patent number: 8974820Abstract: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies.Type: GrantFiled: July 18, 2011Date of Patent: March 10, 2015Assignee: Procaps SASInventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
-
Patent number: 8968775Abstract: Provided are pharmaceutical carriers based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.Type: GrantFiled: March 14, 2014Date of Patent: March 3, 2015Assignee: EyeCRO, LLCInventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
-
Publication number: 20150017238Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.Type: ApplicationFiled: January 3, 2013Publication date: January 15, 2015Applicant: Oramed, Ltd.Inventor: Miriam Kidron
-
Patent number: 8916204Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.Type: GrantFiled: March 13, 2013Date of Patent: December 23, 2014Assignee: Abraxis BioSciences, LLCInventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
-
Patent number: 8911777Abstract: An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.Type: GrantFiled: April 4, 2008Date of Patent: December 16, 2014Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 8900629Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.Type: GrantFiled: December 22, 2011Date of Patent: December 2, 2014Assignee: University of KansasInventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
-
Patent number: 8889161Abstract: The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.Type: GrantFiled: April 27, 2010Date of Patent: November 18, 2014Assignee: Premier Dental Products CompanyInventors: Mark A. Latta, Stephen M. Gross, William A. Mchale
-
Publication number: 20140335172Abstract: Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the eye cavity after ophthalmological procedures using the disclosed rinsing agent in order to prevent the development of long-term complications associated with the emulsified oil droplets.Type: ApplicationFiled: April 29, 2014Publication date: November 13, 2014Applicant: THE UNIVERSITY OF HONG KONGInventors: Ho Cheung SHUM, Sai Hung WONG, Yau Kei CHAN
-
Publication number: 20140314840Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventor: Michael Fantuzzi
-
Patent number: 8865021Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.Type: GrantFiled: November 5, 2004Date of Patent: October 21, 2014Assignee: Camurus ABInventors: Fredrik Joabsson, Fredrik Tiberg
-
Patent number: 8865209Abstract: A method is disclosed for self-administered delivery of a pre-determined amount of liquid medication where a portion of the liquid medication is administered sublingually and the remaining portion is swallowed for and gastro-intestinal absorption.Type: GrantFiled: May 30, 2014Date of Patent: October 21, 2014Inventor: Yuri Busiashvili
-
Patent number: 8865032Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: GrantFiled: August 13, 2013Date of Patent: October 21, 2014Assignee: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi
-
Publication number: 20140302134Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.Type: ApplicationFiled: September 7, 2012Publication date: October 9, 2014Inventor: Roland Saur-Brosch
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Patent number: 8840934Abstract: A method to treat a condition in a patient comprising administering to the patient a therapeutically effective amount of a NH4Cl dosage form, a method for stimulating endogenous interferon production, and related methods, systems and dosage form housings.Type: GrantFiled: January 2, 2009Date of Patent: September 23, 2014Assignee: Rainbow Pharmaceutical SAInventor: Diamantis Kiassos
-
Publication number: 20140271791Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: ALTRIA CLIENT SERVICES INC.Inventors: Munmaya K. Mishra, Gerd Kobal
-
Patent number: 8835509Abstract: The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount of a curcuminoid, an oil phase, a surfactant and a co surfactant.Type: GrantFiled: April 26, 2011Date of Patent: September 16, 2014Assignees: Arbro Pharmaceuticals Ltd., Jamia Hamdard (Hamdard University)Inventors: Kanchan Kohli, Sunny Chopra, Saurabh Arora, Roop K. Khar, Kolappa K. Pillai
-
Publication number: 20140255481Abstract: The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicant: NOVO NORDISK A/SInventor: Florian A. Foeger
-
Patent number: 8815284Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.Type: GrantFiled: June 25, 2004Date of Patent: August 26, 2014Assignee: pSivida US, Inc.Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton
-
Publication number: 20140234410Abstract: A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active ingredient, and at least some of the minicapsules containing a corticosteroid as another active ingredient.Type: ApplicationFiled: April 23, 2014Publication date: August 21, 2014Applicant: SIGMOID PHARMA LTD.Inventors: Joey Moodley, Ivan Coulter
-
Publication number: 20140234411Abstract: The present invention is related to a seamless capsule which easily dissolves in the oral cavity etc. The present invention provides a seamless capsule comprising a capsule content solution, and a capsule shell enclosing the capsule content solution, wherein the capsule shell comprises a gelatin having a bloom value of 50 to 190 and wherein the seamless capsule has a capsule shell-dissolution time of 60 seconds or less when the dissolution time is determined by a disintegration test using water as a test solution.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Inventors: Ryosei Kamaguchi, Osami Nakano, Hisaaki Hatanaka
-
Patent number: 8795720Abstract: The present invention provides a delivery system comprising: (a) a container which is a formed body obtained from a film forming composition comprising at least one polysaccharide or polysaccharide derivative; (b) a liquid fill comprising a matrix composition of at least one solvent which is both polar and hygroscopic or a mixture of solvents each of which is both polar and hygroscopic; and (c) an active agent or a mixture of active agents wherein the active agent is soluble in said polar and hygroscopic solvent or mixture of polar and hygroscopic solvents, and a process for the preparation of said delivery system.Type: GrantFiled: August 29, 2006Date of Patent: August 5, 2014Assignee: Capsugel Belgium NVInventor: Nicolas Madit
-
Patent number: 8771731Abstract: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.Type: GrantFiled: August 18, 2006Date of Patent: July 8, 2014Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Tarek Hamouda, Amy Shih, Andrzej Myc
-
Patent number: 8741341Abstract: The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention.Type: GrantFiled: March 20, 2013Date of Patent: June 3, 2014Assignee: INSYS Therapeutics, Inc.Inventors: Venkat Goskonda, Ashok Chavan, Kiran Amancha, Scott Crisman, Crystal Lopez
-
Patent number: 8734840Abstract: A process is disclosed for preparing polynuclear microcapsules by polymerizing an alkoxysilane at the oil/water interface of a multiple phase emulsion to form a suspension of polynuclear microcapsules. Also disclosed are polynuclear microcapsules optionally comprising a hydrophilic active and uses thereof.Type: GrantFiled: April 4, 2013Date of Patent: May 27, 2014Assignee: Dow Corning CorporationInventors: Leon Marteaux, Brett Zimmerman
-
Perfluorocarbon nano-emulsion containing quantum dot nanoparticles and method for preparing the same
Patent number: 8734762Abstract: The present invention relates to a perfluorocarbon nanoemulsion containing quantum dot nanoparticles and a method for preparing the same, more specifically, relates to a method for preparing a multifunctional perfluorocarbon nanoemulsion which simultaneously shows the fluorine-based magnetic resonance properties of perfluorocarbon and the optical properties of quantum dot nanoparticles, the method comprising dispersing quantum dot nanoparticles, modified with a fluorine end group, in perfluorocarbon, and then adding an aqueous emulsifier solution containing lipid to the dispersion. The disclosed perfluorocarbon nanoemulsion containing quantum dot nanoparticles has excellent biocompatibility and simultaneously shows optical properties and magnetic resonance properties, and thus can be used as a contrast agent for multi-mode molecular imaging. Accordingly, the nanoemulsion can be used to study cell and small-animal molecular imaging in various fields, including biological and medical fields.Type: GrantFiled: August 20, 2008Date of Patent: May 27, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, Yong Taik Lim, Bang Sil Choi, Jung Hyun Han -
Publication number: 20140141076Abstract: The present invention provides: a soft capsule preparation which includes a self-emulsifying composition containing an oily component, an emulsifier, 8% by mass to 20% by mass of a polyhydric alcohol and 2.5% by mass to 5% by mass of water, and a capsule film containing 35% by mass to 50% by mass of a polyhydric alcohol and gelatin, in which capsule film the above-described self-emulsifying composition is encapsulated; a method of producing the soft capsule preparation; a composition for a soft capsule preparation, which is an intermediate product of the soft capsule preparation; and a self-emulsifying composition and a capsule film composition that are used in the composition for a soft capsule preparation.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: FUJIFILM CORPORATIONInventors: Nobuyuki HARAGUCHI, Hiroyuki SAKAGUCHI
-
Patent number: 8728518Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.Type: GrantFiled: August 26, 2005Date of Patent: May 20, 2014Assignee: CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., LtdInventors: Zhentao Liu, Liying Yang, Hanyu Yang, Yuqing Gao, Dongmin Shen, Wenmin Guo, Xiaolong Feng, Jia Zheng
-
Patent number: 8722650Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.Type: GrantFiled: August 23, 2010Date of Patent: May 13, 2014Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
-
Patent number: 8703183Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.Type: GrantFiled: December 24, 2010Date of Patent: April 22, 2014Assignee: Laboratorios Silanes S.A. de C.V.Inventor: Jose Manuel FranciscoOchoa Lara
-
Patent number: 8691878Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: November 12, 2012Date of Patent: April 8, 2014Assignee: AbbVie Inc.Inventors: Jeorg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8673350Abstract: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.Type: GrantFiled: July 21, 2004Date of Patent: March 18, 2014Assignee: Capsugel Belgium NVInventors: Stephen Mark McAllister, Ronald K. Raby, Jr., Adrian Brown
-
Patent number: 8663665Abstract: The invention in one aspect relates to an anti-chafing composition with improved efficacy, in one embodiment, comprising an effective amount of boron nitride suspended in a dermatologically acceptable carrier vehicle. Another embodiment relates to an anti-chafing composition in the form of a powder or a stick containing boron nitride. The present invention also relates to a method of inhibiting or reducing chafing to the skin by topically applying an effective amount of such anti-chafing composition to the skin or to a surface to be in contact with the skin.Type: GrantFiled: October 31, 2006Date of Patent: March 4, 2014Assignee: Momentive Performance Materials Inc.Inventors: Joerg Student, Rickson Sun, Kristi Scherler, Paul Hans, Jon Leist, Gregory W. Shaffer
-
Publication number: 20140044779Abstract: A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH3)3Si—O]—[(CH2)2Si—O]n—[Si(CH3)3]. The second liquid is a polar lipid material. The first and second liquids are capable of forming an unstable dispersion. The unstable dispersion can be stabilized by adding a powderous solid insoluble in the liquids. The powderous solid is selected from pharmacologically active agent, pharmaceutical excipient, and their mixtures. The stabilized dispersion is of a creamy or ointment-like or mouldable form, and can be filled into capsules or moulded into tablets so as to be fit for peroral administration.Type: ApplicationFiled: April 20, 2012Publication date: February 13, 2014Applicant: LIPIDOR ABInventors: Anders Carlsson, Bengt Herslöf, Jan Holmbäck
-
Publication number: 20140044761Abstract: A hybrid encapsulate formulation obtained by mixing a starch/fragrance emulsion with a core-shell capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: International Flavors & Fragrances Inc.Inventors: Yabin Lei, Michael V. Imperiale, Lewis M. Popplewell, Franklin Pringgosusanto, Ralph Gencarelli
-
Publication number: 20140010870Abstract: The present invention relates to a pharmaceutical composition comprising solutions, suspensions of dispersions of inositol, or an isomer thereof, in a vehicle comprising gelatin, glycerol or mixtures thereof.Type: ApplicationFiled: March 21, 2012Publication date: January 9, 2014Applicant: LO.LI. PHARMA S.R.L.Inventor: Vittorio Unfer
-
Publication number: 20140004185Abstract: A pharmaceutical composition for intraperitoneal delivery of an anti-neoplastic agent is provided for treating cancers associated with aberrant mucin expression, preferably ovarian cancer and pancreatic, prostate, metastatic breast, bladder and lung cancers. The composition comprises nanomicelles loaded with the anti-neoplastic agent, and antibodies such as anti-MUC16, anti-MUC1 or anti-MUC4 are conjugated to these nanomicelles. The antibody-bound nanomicelles are optionally embedded in a biodegradable pH- and thermo-responsive hydrogel capable of sol-gel transition at body temperature. The pharmaceutical composition is implantable in the peritoneum, where it transforms into a semi-solid gel at the body's core temperature. In response to pH, the hydrogel swells and releases the antibody-bound nanomicelles. The nanomicelles specifically target mucin antigens on cancer cells.Type: ApplicationFiled: November 28, 2011Publication date: January 2, 2014Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Nthato Chirwa, Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit
-
Patent number: 8617541Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.Type: GrantFiled: February 2, 2012Date of Patent: December 31, 2013Assignee: Soft Gel Technologies, Inc.Inventor: Michael Fantuzzi
-
Publication number: 20130344141Abstract: A concentration and mental performance amplifying formulation comprising rhodiola rosea and geranium oil, together with at least one of vinpocetine, phosphatidylcholine, caffeine and Salix alba (White Willow Bark). In another aspect, there is disclosed a concentration and mental performance amplifying formulation comprising: rhodiola rosea, geranium oil, and at least one of anhydrous caffeine and nicotine. In yet another aspect, there is disclosed a concentration and mental performance amplifying formulation as last described which further comprises: Vinpocetine, or Vincamine together with Huperzine-A, or Vinca minor (Periwinkle) together with Huperzine-A; PhosphatidylCholine or Bacopa monnieri (Brahmi) or Mucuna pruriens; Nicotinamide Adenine Dinucleotide Hydrate; and Salix alba (White Willow Bark). Also described is a method of amplifying concentration and mental performance in a human subject by administering such formulations to such a subject.Type: ApplicationFiled: August 27, 2013Publication date: December 26, 2013Inventor: Michael Scott BUCKLEY
-
Publication number: 20130331466Abstract: A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes.Type: ApplicationFiled: May 27, 2013Publication date: December 12, 2013Inventors: Richard A. Gross, Thavasi Rengathavasi, Amanda Koh, Yifeng Peng
-
Publication number: 20130323303Abstract: A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid. The components of the aqueous micelles are phospholipids and amphiphilic chitosan, and the aqueous micelles enclose an aqueous solution containing a drug. Furthermore, the method of preparing the drug carrier is also provided. Therefore, with the pharmaceutical advantages of lipid-based nanoparticle included low drug leakage and the ability of to overcome the multiple drug resistance, this new formulation were further incorporated with the chitosan and featured with high payload efficiency. The features could enhance intracellular concentration of anti-cancer drug and oral bioavailability.Type: ApplicationFiled: September 10, 2012Publication date: December 5, 2013Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventors: San-Yuan CHEN, Chia-Wei SU, Dean-Mo LIU
-
Patent number: 8591920Abstract: Emulsions of lipophiles such as glycerol monostearate which are compatible with acrylic copolymer emulsions are made stable by using an emulsion stabilizer such as polysorbate 80 in an amount by weight between 1% and 5% of the lipophile and homogenizing the emulsion wherein the emulsion micelles are less than 50 microns. The ability to make a stable emulsion of a lipophile is important in the coating process as it enables preparation and shipment of the lipophilic emulsion to the coater rather than the preparation of a lipophilic emulsion at the time of the coating process which involves a heating and cooling process.Type: GrantFiled: October 28, 2005Date of Patent: November 26, 2013Assignee: Emerson Resources, Inc.Inventor: Charles Signorino
-
Patent number: 8592490Abstract: Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.Type: GrantFiled: December 14, 2007Date of Patent: November 26, 2013Assignee: LEK Pharmaceuticals D.D.Inventors: Igor Legen, Janez Kerc, Polona Jurkovic
-
Publication number: 20130309300Abstract: The present invention relates to nutritional products containing hydroxytyrosol, particularly fond products (i.e.: fortified edible oils and fortified edible oil-containing products) and dietary supplements (i.e.: soft gel capsules containing fortified edible oils) with increased antioxidant capacity to be used as a source of hydroxytyrosol for preventing or treating cardiovascular diseases, plaque build-up in the arteries, arterial hypertension, and metabolic syndrome, thanks to the nutritional supply of an hydroxytyrosol rich composition.Type: ApplicationFiled: November 5, 2012Publication date: November 21, 2013Inventor: PROBELTE PHARMA S.A.
-
Publication number: 20130287844Abstract: The present invention relates to microcapsules comprising a polyurea shell and a core, which contains a pesticide, a water-immiscible solvent A and at least 5 wt % of an aprotic, polar solvent B, which has a solubility in water from 0.5 to 20 g/l at 20° C., based on the total weight of the solvents in the core. It further relates to microcapsules comprising a shell and a core, which contains a pesticide and 2-heptanone; to a method for preparing said mircocapsules; to an aqueous composition comprising said microcapsules; and to a method for controlling phytopathogenic fungi and/or undesired plant growth and/or undesired attack by insects or mites and/or for regulating the growth of plants, with said mircocapsules.Type: ApplicationFiled: January 11, 2012Publication date: October 31, 2013Inventors: Claude Taranta, Thomas Bork, Tina Schroeder-Grimonpont, Britta Katz, Tatjana Sikuljak, Simon Nord, Juergen Distler, Richard A. Warriner, Daniel Bihlmeyer, James Thomas Wofford
-
Patent number: 8569357Abstract: Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.Type: GrantFiled: February 18, 2011Date of Patent: October 29, 2013Assignee: Teikoku Pharma USA, Inc.Inventor: Nabeta Kiichiro
-
Patent number: 8563082Abstract: A device for producing a crosslinked substance, e.g., of crosslinked microcapsules (1) of a crosslinkable capsule substance, in particular crosslinked alginates, is described, having a first dispensing device (2) for dispensing a jet of the crosslinkable capsule substance and a crosslinking device for applying a crosslinking agent to the capsule substance, whereby the crosslinking device has a second dispensing device (5) which directs a jet (9, 13) of the crosslinking agent at the jet or at a layer of the capsule substance.Type: GrantFiled: July 16, 2009Date of Patent: October 22, 2013Assignee: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventors: Ulrich Zimmermann, Heiko Zimmermann
-
Patent number: 8562975Abstract: The present invention relates to a method for stabilizing reduced coenzyme Q10, which is useful as an ingredient in good foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc., and to a composition therefor. The composition comprises reduced coenzyme Q10, a fat and oil (excluding olive oil) and/or a polyol, and doesn't substantially inhibit the stabilization of reduced coenzyme Q10. Additionally, the composition is a reduced coenzyme Q10-containing composition which comprises reduced coenzyme Q10, a polyglycerol fatty acid ester, and a fat and oil and/or a polyol.Type: GrantFiled: January 20, 2003Date of Patent: October 22, 2013Assignee: Kaneka CorporationInventors: Yasuyoshi Ueda, Takahiro Ueda, Tadao Ono, Shiro Kitamura, Kenji Fujii, Kazunori Hosoe